UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000007244
Receipt number R000008538
Scientific Title A randomized phase II study of Gemcitabine or Gemcitabine + S-1 as adjuvant chemotherapy for resected biliary tract cancer
Date of disclosure of the study information 2012/02/10
Last modified on 2015/02/12 21:05:28

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A randomized phase II study of Gemcitabine or Gemcitabine + S-1 as adjuvant chemotherapy for resected biliary tract cancer

Acronym

A randomized phase II study of Gemcitabine or Gemcitabine + S-1 as adjuvant chemotherapy for resected biliary tract cancer

Scientific Title

A randomized phase II study of Gemcitabine or Gemcitabine + S-1 as adjuvant chemotherapy for resected biliary tract cancer

Scientific Title:Acronym

A randomized phase II study of Gemcitabine or Gemcitabine + S-1 as adjuvant chemotherapy for resected biliary tract cancer

Region

Japan


Condition

Condition

Biliary tract cancer (intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, gallbladder carcinoma)

Classification by specialty

Hepato-biliary-pancreatic surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the efficacy and safety of Gemcitabine or Gemcitabine + S-1 as adjuvant chemotherapy in patients with resected biliary tract cancer.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Phase II


Assessment

Primary outcomes

Disease Free Survival

Key secondary outcomes

Overall Survival
Safety
Completion rate


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

GEM : day 1, 8, 15 1000mg/m2 IV
q4 weeks
12 cycles

Interventions/Control_2

GEM : day 8, 15 1000mg/m2 IV
TS-1 : day 1-14 60mg/m2 PO
q3 weeks
16 cycles

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

(1) Biliary tract cancer. Histologically or cytologically confirmed adenocarcinoma, adenosquamous carcinoma. Surgical resection (Cur B/C, Nodal status (+))
(2) No previous chemotherapy against biliary tract cancer.
(3) No previous radiotherapy against biliary tract cancer.
(4) EOCG performance status of 0-2
(5) Age over 20
(6) Have a life expectancy of at least 2 months
(7) Sufficient organ function defined as :
Hb over 9.0g/dl
WBC over 3000/mm3
ANC over 1500/mm3
PLT over 100,000/mm3
AST/ALT under upper limit X 2.5
T-Bil & under upper limit X 3
Creatinine upper limit
(8) Written informed consent

Key exclusion criteria

(1) active interstitial pneumonia
(2) unstable pleural effusion
(3) with metastasis
(4) patients with uncured other malignancies
(5) active severe infection
(6) patients with severe complication
(7) patients with uncontrollable angina pectoris or a new onset of myocardial infarction within 3 months
(8) uncontrollable diabetes mellitus, hypertension
(9) psychiatric disorder
(10) women in pregnancy, potential pregnancy, or breast feeding
(11) other inappropriate cases according to primary doctor's evaluation

Target sample size

130


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Masaru Miyazaki

Organization

Chiba University Graduate School of Medicine

Division name

Department of General Surgery

Zip code


Address

1-8-1 Inohana Chuo-ku, Chiba

TEL

043-226-2103

Email

masaru@faculty.chiba-u.jp


Public contact

Name of contact person

1st name
Middle name
Last name Atsushi Kato

Organization

Chiba University Graduate School of Medicine

Division name

Department of General Surgery

Zip code


Address

1-8-1 Inohana Chuo-ku, Chiba

TEL

043-226-2103

Homepage URL


Email

akato@faculty.chiba-u.jp


Sponsor or person

Institute

Adjuvant Therapy for BTC Research Group

Institute

Department

Personal name



Funding Source

Organization

Chiba University Graduate School of Medicine, Department of General Surgery

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

千葉大学病院〔千葉県)、平和病院(神奈川県)、大網病院(千葉県)、小田原市立病院(神奈川県)、上都賀総合病院(栃木県)、匝瑳市民病院(千葉県)、君津中央病院(千葉県)、さいたま赤十字病院(埼玉県)、聖隷横浜病院(神奈川県)、船橋中央病院(千葉県)、浦賀病院(神奈川県)、済生会習志野病院(千葉県)、千葉市立青葉病院(千葉県)、千葉市立海浜病院(千葉県)、多摩総合医療センター(東京都)、千葉医療センター(千葉県)、千葉労災病院(千葉県)、須坂病院(長野県)、成田赤十字病院(千葉県)、深谷赤十字病院(埼玉県)、松戸市立病院(千葉県)、杏雲堂病院(東京都)


Other administrative information

Date of disclosure of the study information

2012 Year 02 Month 10 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2008 Year 10 Month 10 Day

Date of IRB


Anticipated trial start date

2009 Year 01 Month 01 Day

Last follow-up date

2014 Year 12 Month 01 Day

Date of closure to data entry

2015 Year 07 Month 01 Day

Date trial data considered complete

2015 Year 12 Month 01 Day

Date analysis concluded

2015 Year 12 Month 01 Day


Other

Other related information



Management information

Registered date

2012 Year 02 Month 07 Day

Last modified on

2015 Year 02 Month 12 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000008538


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name